One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Immediate-release scope. Do not apply this target or titration to extended-release memantine.
Selected IR renal target agrees; this does not validate the full dated mirror or imply equivalence to ER.
What to reconcile: Use the release-specific maintenance limit and review initial/restart titration.
Open this note and its source referencesUse the release-specific maintenance limit and review initial/restart titration.
The severe-renal target agrees with the selected IR label. The November 2018 mirror contains encoding damage in its range dash; the dose band is separately legible in official labeling.
Dose escalation is at least one week apart; a prolonged interruption can require lower-dose restart and retitration.
| Cockcroft-Gault CrCl (mL/min) | Source-specific instruction |
|---|---|
| 5-29 | Target 5 mg twice daily |
| Mild/moderate renal impairment | No renal adjustment recommended in selected labeling |
Memantine IR - renal maintenance target
| Cockcroft-Gault CrCl (mL/min) | Source-specific instruction |
|---|---|
| 5-29 | Target 5 mg twice daily |
| Mild/moderate renal impairment | No renal adjustment recommended in selected labeling |
The severe-renal target agrees with the selected IR label. The November 2018 mirror contains encoding damage in its range dash; the dose band is separately legible in official labeling.
Dose escalation is at least one week apart; a prolonged interruption can require lower-dose restart and retitration.
RDM64-rxlist-memantine-911c54e3a3-C1 · Source locator: Dosage and Specific Populations / Renal Impairment.
The severe-renal target agrees with the selected IR label. The November 2018 mirror contains encoding damage in its range dash; the dose band is separately legible in official labeling.
Dose escalation is at least one week apart; a prolonged interruption can require lower-dose restart and retitration.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=memantine&s1=RDM64-rxlist-memantine-911c54e3a3&h1=16afa1ffd748d9f1ade6550b99ed01647ec121b439459543c039e63eadad1f49